Challenges in the diagnosis of Parkinson's disease
Parkinson's disease is the second most common neurodegenerative disease and its
prevalence has been projected to double over the next 30 years. An accurate diagnosis of …
prevalence has been projected to double over the next 30 years. An accurate diagnosis of …
Developing the ATX (N) classification for use across the Alzheimer disease continuum
Breakthroughs in the development of highly accurate fluid and neuroimaging biomarkers
have catalysed the conceptual transformation of Alzheimer disease (AD) from the traditional …
have catalysed the conceptual transformation of Alzheimer disease (AD) from the traditional …
Assessment of heterogeneity among participants in the Parkinson's Progression Markers Initiative cohort using α-synuclein seed amplification: a cross-sectional study
A Siderowf, L Concha-Marambio, DE Lafontant… - The Lancet …, 2023 - thelancet.com
Background Emerging evidence shows that α-synuclein seed amplification assays (SAAs)
have the potential to differentiate people with Parkinson's disease from healthy controls. We …
have the potential to differentiate people with Parkinson's disease from healthy controls. We …
Revised criteria for diagnosis and staging of Alzheimer's disease: Alzheimer's Association Workgroup
CR Jack Jr, JS Andrews, TG Beach… - Alzheimer's & …, 2024 - Wiley Online Library
Abstract The National Institute on Aging and the Alzheimer's Association convened three
separate work groups in 2011 and single work groups in 2012 and 2018 to create …
separate work groups in 2011 and single work groups in 2012 and 2018 to create …
Propagative α-synuclein seeds as serum biomarkers for synucleinopathies
A Okuzumi, T Hatano, G Matsumoto, S Nojiri, S Ueno… - Nature medicine, 2023 - nature.com
Abnormal α-synuclein aggregation is a key pathological feature of a group of
neurodegenerative diseases known as synucleinopathies, which include Parkinson's …
neurodegenerative diseases known as synucleinopathies, which include Parkinson's …
Neuropathology and molecular diagnosis of Synucleinopathies
Synucleinopathies are clinically and pathologically heterogeneous disorders characterized
by pathologic aggregates of α-synuclein in neurons and glia, in the form of Lewy bodies …
by pathologic aggregates of α-synuclein in neurons and glia, in the form of Lewy bodies …
Detection of neuron-derived pathological α-synuclein in blood
To date, no reliable clinically applicable biomarker has been established for Parkinson's
disease. Our results indicate that a long anticipated blood test for Parkinson's disease may …
disease. Our results indicate that a long anticipated blood test for Parkinson's disease may …
Discriminating α-synuclein strains in Parkinson's disease and multiple system atrophy
Synucleinopathies are neurodegenerative diseases that are associated with the misfolding
and aggregation of α-synuclein, including Parkinson's disease, dementia with Lewy bodies …
and aggregation of α-synuclein, including Parkinson's disease, dementia with Lewy bodies …
Protein transmission in neurodegenerative disease
Most neurodegenerative diseases are characterized by the intracellular or extracellular
aggregation of misfolded proteins such as amyloid-β and tau in Alzheimer disease, α …
aggregation of misfolded proteins such as amyloid-β and tau in Alzheimer disease, α …
Detection of α-synuclein in CSF by RT-QuIC in patients with isolated rapid-eye-movement sleep behaviour disorder: a longitudinal observational study
A Iranzo, G Fairfoul, ACN Ayudhaya… - The Lancet …, 2021 - thelancet.com
Background Isolated rapid-eye-movement (REM) sleep behaviour disorder (IRBD) can be
part of the prodromal stage of the α-synucleinopathies Parkinson's disease and dementia …
part of the prodromal stage of the α-synucleinopathies Parkinson's disease and dementia …